Nanobio and Nanomedicine

The company's proprietary NanoCrystal® technology can enable formulation and improve compound activity and final product characteristics for poorly water-soluble compounds.

The company's mission is to develop and license R&D projects in Nanotechnology applied to Life Sciences. Endor is also developing pioneer in-house projects in novel Nanomaterials.

Serving as a contract research organization, Endotherm Life Science Molecules is a provider of medicinally relevant compounds for the discovery and development of novel small molecule drugs. The product range includes focused compound libraries, building blocks and reagents for the development of biochemical assays (fluorescent and bioluminescent dyes).

EnGeneIC aims to revolutionize the treatment of cancer by targeted delivery of drugs or siRNAs using the same versatile nano-sized delivery vehicle to address the complexities found in cancer cells.

Ensemble Discovery is utilizing DNA Programmed Chemistry (DPC), an innovative method for creating new chemical bonds. Ensemble integrates DPC into a nanoscale selection system that combines chemistry, biology and informatics to discover novel compounds.

The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.

Epeius' proprietary Targeted Delivery System technology consists of three separate components: (i) a 'pathotropic' or disease seeking guidance system, (ii) a stealth nanoparticle vector or vehicle, and (iii) a designer 'killer' gene that compels cancer cells and tumor-associated vasculature to self-destruct without causing collateral damage to non-target tissues.

Epocal is implementing an entire blood diagnostic 'laboratory on a chip' in FlexCard™ technology, with some elements are fabricated in media with micrometer or nanometer scale flow channels or pores.

Develops and supplies molecular diagnostics products.

Develops food additives with specially formulated nanoparticles which improve bioavailability.

Develops analytical devices based on biosensors with the aid of nanobiotechnology.

The company develops unique molecular delivery systems. Its spherical micrometer sizes polymer particles act like micro sponges and absorb molecules while the sub-micrometer sized Hollow silica shells have an internal void space and act much like a standard container.